Latest Biotech News

Kailera Therapeutics moved to the public markets, filing plans for an IPO to fund its obesity portfolio, led by weekly GLP-1/GIP agonist ribupatide (KAI-9531). The Boston-based biotech, backed by...

Eli Lilly expanded its AI drug discovery collaboration with Insilico Medicine, signing a deal that could total $2.75 billion in development, regulatory, and commercial milestones. Lilly will pay...

Washington University School of Medicine in St. Louis announced that the U.S. FDA granted Breakthrough Therapy Designation to a CAR-T cell treatment targeting uPAR for solid tumors. The therapy...

Novartis agreed to acquire Excellergy, adding an anti-IgE antibody program (Exl-111) currently in Phase I testing. The deal broadens Novartis’ immune and inflammation pipeline, with Exl-111...

ICON partnered with institutional review board and clinical trial management provider Advarra to build an integrated, AI-driven clinical site network model aimed at speeding study startup. The...

Takeda announced plans to lay off nearly 250 workers at its Cambridge, Massachusetts site, beginning in July, after a board-approved cost-saving plan approved March 25. The workforce reduction is...

Viridian Therapeutics disclosed topline Phase 3 results for elegrobart (formerly VRDN-003) in active thyroid eye disease, reporting that the subcutaneous, half-life-extended IGF-1R antibody met a...

United Therapeutics said its second Phase 3 trial of Tyvaso (treprostinil) for idiopathic pulmonary fibrosis met endpoints, strengthening the company’s case for a supplemental NDA and potential...

Boston Scientific presented data from the Champion-AF trial showing that Watchman FLX provided superior protection from bleeding compared with non-vitamin K oral anticoagulants in atrial...

Blackstone announced it closed its Blackstone Life Sciences VI fund at $6.3 billion, the largest life sciences private investment vehicle it has raised. The new fund is nearly 40% larger than the...

Rocket Pharmaceuticals secured FDA approval for Kresladi, its gene therapy for leukocyte-adhesion deficiency type 1 (LAD-1). The company said the approval makes Kresladi the first gene therapy...

United Therapeutics’ Tyvaso (treprostinil) hit endpoints in a second phase 3 idiopathic pulmonary fibrosis (IPF) study, strengthening its case for a supplemental NDA review. The trial reportedly...

ICON partnered with Advarra to build an integrated, AI-driven site network aimed at reducing trial startup delays and easing operational bottlenecks. The collaboration connects ICON’s trial...

Eli Lilly expanded its AI drug discovery strategy through a multibillion-dollar deal with Insilico Medicine. The company will pay $115 million upfront, with up to $2.75 billion in milestone...

Data at the 2026 American Academy of Dermatology meeting pointed to intensified competition in atopic dermatitis as targeted oral therapies move closer to challenging injected biologics. The...

Kailera Therapeutics filed for an IPO to fund its obesity pipeline, spotlighting ribupatide, a weekly GLP-1/GIP agonist in late-stage development. The company said ribupatide delivered about 18%...

Takeda announced additional workforce reductions, starting with nearly 250 Cambridge-area employees as part of a broader cost-saving plan. A state filing stated layoffs begin in July, though some...

The U.S. FDA is considering how to handle its National Priority Voucher (CNPV) program after its introduction last year. The provided material says the program aims to create an ultrafast review...

Karolinska Institutet, Karolinska University Hospital, and SciLifeLab integrated whole genome sequencing into routine rare-disease diagnostics at Karolinska University Hospital. The initiative...

Researchers reported the completion of the first-ever clinical trial using nuclease-free, homologous recombination-dependent gene editing in pediatric patients with methylmalonic acidemia (MMA)....